Additional lots of losartan recalled due to potential cancer risk

Sandoz Canada and Sanis Health are recalling all lots of prescription losartan tablets due to the presence of an azido impurity above the acceptable limit. The impurity is a mutagen and can create a heightened cancer risk over time if allowed to rise above certain levels.

The news, announced in a new advisory from Health Canada, marks the latest in a series of recalls of antihypertensive medications in Canada over the last several months. Previous recalls have included losartan, irbesartan and valsartan—all were related to the same azido impurity.

“Continue taking your medication unless you have been advised to stop by your healthcare provider,” Health Canada warned in its advisory. “Not treating your condition may pose a greater health risk.”

Read the full advisory—which includes all updates since the first announcement back in May—here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup